Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novartis Pharmaceuticals Corporation
EIR
•Novartis Pharmaceuticals Corporation•September 7, 2017

Novartis Pharmaceuticals Corporation – FDA EIR, Sep 7, 2017

Record Details

An FDA inspection of Novartis Pharmaceuticals Corp.'s East Hanover, NJ facility was conducted from August 28 to September 7, 2017. The inspection, initiated by the Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance, focused on compliance with Good Laboratory Practice (GLP) for non-clinical drug studies. This unannounced inspection followed a previous GLP inspection in 2014, which resulted in "No Action Indicated." During the current review, the inspectors assessed various aspects, including the firm's transition from active GLP animal testing to maintaining primarily GLP archives and analytical equipment. The inspection covered the firm's training program, Institutional Animal Care and Use Committee (IACUC) procedures, records retention, and audited three non-clinical GLP studies involving rats, dogs, and monkeys. Notably, no deficiencies or violations were identified, and a Form FDA-483 (Inspectional Observations) was not issued. In a general discussion with management at the closeout meeting, the FDA provided recommendations. These included the importance of maintaining GLP status for equipment containing raw data, ensuring the secure retention and accessibility of all GLP records, slides, and blocks, and verifying accessibility of externally archived documents. Novartis was also advised to maintain a clear method for retrieving past GLP studies for future regulatory reviews and to inform the FDA of any changes to the location of archived GLP materials. The company's Global Head of Preclinical Safety and Toxicology committed to upholding GLP standards for their archive.

Company
Novartis Pharmaceuticals Corporation
Inspection date
September 7, 2017
Product type
drugs
Office
New Jersey District Office
People
  • Daniel Lapadula (company_representative)
  • Raviprakash R. Dugyala (company_representative)
  • M. Craig Keselica (company_representative)
  • Wei Zhou (company_representative)
  • Jimmy Flarakos (company_representative)
View Company Profile

ID · faf8091c-3829-4500-a76d-e0a68515ed42

Violation Codes1
21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for Novartis Pharmaceuticals Corporation
  • 483 - 2023-08-21August 21, 2023
  • 483 - 2018-12-14December 14, 2018
  • EIR - 2017-03-02March 2, 2017
  • EIR - 2017-01-24January 24, 2017
  • 483 - 2017-01-24January 24, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novartis Pharmaceuticals Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.